People with hypoparathyro idism need new treatment options and we are working with urgency to resolve the FDAs concerns  with the goal of bringing Trans Con PTH to patients in the US  As recently announced  145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years and the US